News

Testata Area News
  1. Published: 2 Dec 2020

    Ovid Therapeutics

    Ovid Therapeutics yesterday announced the topline results from the Company’s Phase III NEPTUNE clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome.